1313816-36-2

Upstream product

• 58772-72-8 3,6-diacetylnormethylmorphine 
• 561-27-3 Diamorphine 
• 1502-95-0 heroin hydrochloride 
• 53425-20-0 norheroin hydrochloride 
• 1313816-31-7 C₂HF₃O₂*C₂₄H₃₀N₂O₅ 
• 129431-12-5 3-(triphenylmethylthio)propionic acid N-hydroxysuccinimide ester 
• 1313816-26-0 (4aR,7S,7aR,12bS)-3-(3-((tert-butoxycarbonyl)amino)butyl)-2,3,4,4a,7,7a-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diyl diacetate 

Downstream Products

• 1313816-39-5 N-(3-(4aR,7S,7aR,12bS)-7,9-dihydroxy-4,4a,7,7a-tetrahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3(2H)-yl)butyl-3-(tritylthio)propanamide 

Relevant academic research and scientific papers

Development of a Clinically Viable Heroin Vaccine

Heroin is a highly abused opioid and incurs a significant detriment to society worldwide. In an effort to expand the limited pharmacotherapy options for opioid use disorders, a heroin conjugate vaccine was developed through comprehensive evaluation of hap

HEROIN HAPTENS, IMMUNOCONJUGATES AND RELATED USES

The present invention provides novel heroin hapten compounds and heroin immunoconjugates which can be used for in vivo production of antibodies that specifically bind to heroin and its psychoactive metabolites. The invention also provides methods of using

A vaccine strategy that induces protective immunity against heroin

Heroin addiction is a wide-reaching problem with a spectrum of damaging social consequences. A vaccine capable of blocking heroin's effects could provide a long-lasting and sustainable adjunct to heroin addiction therapy. Heroin, however, presents a parti